Tuesday, 11 May 2021 01:47 GMT

Reminder: Invitation to Targovax's Capital Markets Day 18 February 2021

(MENAFN - PR Newswire) OSLO, Feb. 18, 2021 /PRNewswire/ -- Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Markets Day for investors, analysts and journalists today at 2:30 PM CET. The Capital Markets Day will feature presentations from executive management and Alexander Shousthari, Clinical Director Melanoma Services at Memorial Sloan Kettering Cancer Center, and will be webcast live and accessible at

 Based on the strong clinical data that are now generated on ONCOS-102, Targovax has a solid fundament to move into late stage clinical development. We also have a broader pipeline of preclinical assets that could create a broader horizon of opportunities in the future. The Capital Markets day will feature presentations updating the market on these aspects.

The agenda will be as follows:

Agenda & speakers

2:30-2:40 PM


Øystein Soug, CEO, Targovax

2:40-3:25 PM

Anti-PD1 refractory melanoma

Alexander N. Shoushtari, MD

3:25-3:45 PM

ONCOS-102 development program

Magnus Jäderberg, MD, CMO, Targovax

5-minute break

3:50-4:05 PM

Immune activation

Victor Levitsky, PhD CSO, Targovax

4:05-4:15 PM

Preclinical pipeline update

Victor Levitsky, PhD, CSO, Targovax

4:15-4:25 PM

4Q update

Torbjørn Furuseth, MD, CFO, Targovax

4:25 PM

Closing remarks

Øystein Soug, CEO, Targovax

The presentations will be made available on the company's website after

The presentations will be made available on the company's website after the end of the meeting. Questions can be submitted through the webcast throughout the event.


Dr. Alexander Shoushtari is a renowned expert in melanoma, with a research focus on checkpoint refractory melanomas. He is a Clinical Director and Assistant attending physician at Melanoma Services, Dept of Medicine, Memorial Sloan Kettering Cancer Center. Dr. Alexander Shoushtari is Principal investigator of several immunotherapy trials, including the ONCOS-102 phase I trial in CPI refractory advanced melanoma. 

For further information, please contact: Renate BirkeliInvestor RelationsPhone: +47 922 61 624Email: [email protected]

Media enquires: Andreas Tinglum - Corporate Communications (Norway)Phone: +47 9300 1773Email: [email protected]

IR enquires: Kim Sutton Golodetz - LHA Investor Relations (US)Email: [email protected] Phone: +1 212-838-3777

This information was brought to you by Cision

SOURCE Targovax


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.